Acadia Pharmaceuticals ACAD Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $177.7M-44.4% | $319.59M+69.4% | $188.66M+64.3% | $114.85M-22.1% | ||
| $641.99M+47.1% | $436.4M+74.4% | $250.21M-17.1% | $301.98M-19.1% | ||
| $7.85M-10.5% | $8.77M+52.0% | $5.77M0.0% | $5.77M0.0% | ||
| $121.46M+23.0% | $98.74M+0.5% | $98.27M+58.0% | $62.2M-3.4% | ||
| $4.89M+10.6% | $4.42M-70.6% | $15.07M+4,960% | -$310K— | ||
| $76.7M+10.0% | $69.74M+1,407% | $4.63M-6.0% | $4.92M-20.8% | ||
| $26.77M+350% | $5.96M+45.9% | $4.08M+361% | $885K-9.5% | ||
| $1.06B+13.2% | $938.32M+52.3% | $616.13M+21.3% | $507.94M-17.8% | ||
| $7.51M+78.2% | $4.22M-8.6% | $4.61M-23.4% | $6.02M-25.2% | ||
| $47.35M+1.7% | $46.57M-10.2% | $51.86M-6.7% | $55.57M-4.6% | ||
| $108.89M-9.1% | $119.78M+82.9% | $65.49M— | $0— | ||
| $249.88M— | $0— | —— | —— | ||
| $3.9M+985% | $359K-24.6% | $476K-93.7% | $7.59M+89.8% | ||
| $1.56B+31.7% | $1.19B+58.6% | $748.96M+27.4% | $587.81M-16.0% | ||
| $266.21M-29.7% | $378.68M+60.0% | $236.71M+110% | $112.88M+26.6% | ||
| $11.63M+16.8% | $9.96M+5.9% | $9.41M+1.1% | $9.31M+12.1% | ||
| $277.11M-29.8% | $394.87M+55.3% | $254.25M+102% | $125.63M+30.8% | ||
| $40.55M-3.5% | $42.04M-12.1% | $47.8M-9.3% | $52.7M-6.1% | ||
| $52.19M+0.4% | $52M-9.1% | $57.21M-7.7% | $62M-3.8% | ||
| $19.14M+6.0% | $18.06M+19.2% | $15.15M+66.9% | $9.07M+29.0% | ||
| $336.81M-26.0% | $454.96M+43.4% | $317.2M+69.3% | $187.4M+17.7% | ||
| $0— | $0— | $0— | $0— | ||
| $16K0.0% | $16K0.0% | $16K0.0% | $16K0.0% | ||
| $3.04B+3.5% | $2.94B+2.6% | $2.86B+3.3% | $2.77B+2.8% | ||
| -$1.81B+17.7% | -$2.2B+9.3% | -$2.43B-2.6% | -$2.37B-10.0% | ||
| $1.45M+395% | $292K+1,117% | $24K+102% | -$975K-408% | ||
| $1.23B+67.5% | $732.79M+69.7% | $431.76M+7.8% | $400.41M-26.0% | ||
| $1.56B+31.7% | $1.19B+58.6% | $748.96M+27.4% | $587.81M-16.0% | ||
| $641.99M+47.1% | $436.4M+74.4% | $250.21M-17.1% | $301.98M-19.1% | ||
| $3.9M+985% | $359K-24.6% | $476K-93.7% | $7.59M+89.8% | ||
| $47.35M+1.7% | $46.57M-10.2% | $51.86M-6.7% | $55.57M-4.6% | ||
| $249.88M— | $0— | —— | —— | ||
| $108.89M-9.1% | $119.78M+82.9% | $65.49M— | $0— | ||
| $47.35M+1.7% | $46.57M-10.2% | $51.86M-6.7% | $55.57M-4.6% | ||
| $3.9M+985% | $359K-24.6% | $476K-93.7% | $7.59M+89.8% | ||
| $34.67M+58.0% | $21.95M-38.7% | $35.82M+440% | $6.64M-15.8% | ||
| $47.35M+1.7% | $46.57M-10.2% | $51.86M-6.7% | $55.57M-4.6% | ||
| $3.9M+985% | $359K-24.6% | $476K-93.7% | $7.59M+89.8% | ||
| $266.21M-29.7% | $378.68M+60.0% | $236.71M+110% | $112.88M+26.6% | ||
| $266.21M-29.7% | $378.68M+60.0% | $236.71M+110% | $112.88M+26.6% | ||
| $52.19M+0.4% | $52M-9.1% | $57.21M-7.7% | $62M-3.8% | ||
| $3.04B+3.5% | $2.94B+2.6% | $2.86B+3.3% | $2.77B+2.8% | ||
| $16K0.0% | $16K0.0% | $16K0.0% | $16K0.0% | ||
| $0— | $0— | $0— | $0— | ||
| $26.77M+350% | $5.96M+45.9% | $4.08M+361% | $885K-9.5% | ||
| $76.7M+10.0% | $69.74M+1,407% | $4.63M-6.0% | $4.92M-20.8% | ||
| $59.53M+6.9% | $55.68M+42.4% | $39.09M+82.7% | $21.4M-10.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Acadia Pharmaceuticals cover its short-term obligations?
- Its current ratio is 3.59 — current assets exceed current liabilities.
- Where does Acadia Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Acadia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.